The company has developed an innovative approach to treating recurrent brain tumors by combining a conformable collagen matrix with brachytherapy (radiation) seeds. Their first product, GammaTile™, has multiple patents and has the potential to revolutionize treatment for over 176,000 patients per year in the US alone. Clinical trials at Barrow Neurological Institute have shown significant clinical improvement in 120 patients treated with GammaTile™.